Skip to main content
Premium Trial:

Request an Annual Quote

Orchid's Q1 Sales Rise 12 Percent as Losses Slide 75 Percent on Reorg

NEW YORK (GenomeWeb News) — Orchid Cellmark today said first-quarter revenue rose 12 percent, R&D spending inched up a hair, and losses receded 75 percent.
Total receipts for the three months ended March 31 increased to $14.1 million from $12.6 million year over year due mostly to an increase in forensic casework in the US and UK.
However, those gains were offset in part by a decrease in testing services to the Federal Bureau of Investigation.
R&D spending increased slightly to $279,000 from $278,000 year over year.
Losses in the quarter declined to $1.7 million $6.6 million year over year, due in part to rising gross margin and trimmed expenses that resulted from a reorganization the company implemented last year, Orchid said.
Orchid said it had around $23.9 million in cash and equivalents as of March 31.
Orchid CEO Thomas Bologna said the company is currently “in a good position to take advantage of strategic opportunities for growth.” He did not elaborate.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.